NPS Pharmaceuticals, Inc.  

(Public, NASDAQ:NPSP)   Watch this stock  
Find more results for GEORGE A. NADER�
29.29
0.00 (0.00%)
Pre-market: 29.75 +0.46 (1.57%)
Jul 22, 8:45AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 17.73 - 39.68
Open     -
Vol / Avg. 200.00/1.48M
Mkt cap 3.11B
P/E     -
Div/yield     -
EPS -0.13
Shares 106.33M
Beta 0.50
Inst. own 98%
Aug 14, 2014
NPS Pharmaceuticals Inc at Canaccord Genuity Growth Conference - 10:00AM EDT - Add to calendar
Aug 4, 2014
Q2 2014 NPS Pharmaceuticals Earnings Release (Estimated) Add to calendar
Jun 10, 2014
NPS Pharmaceuticals at Goldman Sachs Healthcare Conference
Jun 2, 2014
NPS Pharmaceuticals at Jefferies Global Healthcare Conference - Webcast
May 13, 2014
NPS Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference - Webcast
May 8, 2014
Q1 2014 NPS Pharmaceuticals Earnings Release
May 8, 2014
Q1 2014 NPS Pharmaceuticals Earnings Conference Call - Webcast
May 6, 2014
NPS Pharmaceuticals Annual Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -14.93% -8.68%
Operating margin -6.69% -0.96%
EBITD margin - 0.73%
Return on average assets -9.23% -6.09%
Return on average equity -25.09% -53.75%
Employees 207 -
CDP Score - -

Address

550 HILLS DRIVE
BEDMINSTER, NJ 07921
United States - Map
+1-908-4505300 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The Company�s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the United States Food and Drug Administration (FDA) during the year ended December 31, 2012, for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. Natpara is the recombinant full-length human parathyroid hormone (rhPTH (1-84)), which is developing as a hormone replacement therapy for hypoparathyroidism, a rare hormone deficiency disorder, in which patients are physiologically unable to regulate the levels of calcium and phosphates in their blood due to insufficient levels of endogenous parathyroid hormone (PTH).

Officers and directors

Peter G. Tombros Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Francois Nader M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Luke M. Beshar CPA Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Roger J. Garceau M.D. Executive Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Christine Mikail Senior Vice President - Legal Affairs, General Counsel
Bio & Compensation  - Reuters
Glenn R. Melrose Senior Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Eric Pauwels Chief Commercial Officer, Senior Vice President
Age: 52
Bio & Compensation  - Reuters
Joseph J. Rogus Vice President - Technical Operations and Supply Chain Management
Age: 67
Bio & Compensation  - Reuters
Susan E. Graf Vice President - Corporate Development and Strategy
Age: 41
Bio & Compensation  - Reuters
Michael W. Bonney Independent Director
Age: 55
Bio & Compensation  - Reuters